Synta Pharmaceuticals

Industry group: Drugs

Headquarters: Pennsylvania

Overview

Average pay of disclosed executives at Synta Pharmaceuticals

Annual data

2018

On May 15, 2019, Synta Pharmaceuticals reported executive compensation for fiscal year 2018.

NamePositionCompensationDetails
Paul A. FriedmanChairman and Chief Executive Officer$5,628,666
Rebecca TaubChief Medical Officer, Executive Vice President, Research & Development$4,340,446
Marc R. SchneebaumSenior Vice President, Chief Financial Officer$3,366,100

Paul A. Friedman — Chairman and Chief Executive Officer — received the highest compensation: $5,628,666 in total.

In addition, Rebecca Taub — Chief Medical Officer, Executive Vice President, Research & Development — received a total compensation of $4,340,446; Marc R. Schneebaum received $3,366,100.

The company's median employee pay was $804,000.

2017

On April 27, 2018, Synta Pharmaceuticals reported executive compensation for fiscal year 2017.

NamePositionCompensationDetails
Paul A. FriedmanChief Executive Officer$1,364,982
Rebecca TaubChief Medical Officer, Executive Vice President, Research & Development$1,091,795
Marc R. SchneebaumSenior Vice President, Chief Financial Officer$970,244

Paul A. Friedman — Chief Executive Officer — received the highest compensation: $1,364,982 in total.

In addition, Rebecca Taub — Chief Medical Officer, Executive Vice President, Research & Development — received a total compensation of $1,091,795; Marc R. Schneebaum received $970,244.

2016

NamePositionCompensationDetails
Paul A. FriedmanChief Executive Officer$3,985,968
Rebecca TaubChief Medical Officer, Executive Vice President, Research & Development$1,654,018
Marc R. SchneebaumSenior Vice President, Chief Financial Officer$1,685,622

Paul A. Friedman — Chief Executive Officer — received the highest compensation: $3,985,968 in total.

In addition, Marc R. Schneebaum — Senior Vice President, Chief Financial Officer — received a total compensation of $1,685,622; Rebecca Taub received $1,654,018.

2013

On April 30, 2014, Synta Pharmaceuticals reported executive compensation for fiscal year 2013.

NamePositionCompensationDetails
Safi R. BahcallFormer President and Chief Executive Officer$2,328,916
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$763,897
Steven BernitzSenior Vice President, Chief Business Officer$651,480
Vojo VukovicSenior Vice President, Chief Medical Officer$1,260,403
Amar SinghFormer Senior Vice President, Chief Business Officer$911,184
Sumant RamachandraFormer President, Research and Development$2,563,140

Sumant Ramachandra — Former President, Research and Development — received the highest compensation: $2,563,140 in total.

In addition, Safi R. Bahcall — Former President and Chief Executive Officer — received a total compensation of $2,328,916; Vojo Vukovic received $1,260,403; Amar Singh received $911,184; Keith S. Ehrlich received $763,897; Steven Bernitz received $651,480.

2012

On April 29, 2013, Synta Pharmaceuticals reported executive compensation for fiscal year 2012.

NamePositionCompensationDetails
Wendy RiederVice President, Intellectual Property and Legal Affairs, General Counsel$622,938
Safi R. BahcallFormer President and Chief Executive Officer$2,059,291
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$624,554
Vojo VukovicSenior Vice President, Chief Medical Officer$900,181
Amar SinghFormer Senior Vice President, Chief Business Officer$804,179

Safi R. Bahcall — Former President and Chief Executive Officer — received the highest compensation: $2,059,291 in total.

In addition, Vojo Vukovic — Senior Vice President, Chief Medical Officer — received a total compensation of $900,181; Amar Singh received $804,179; Keith S. Ehrlich received $624,554; Wendy Rieder received $622,938.

2011

NamePositionCompensationDetails
Safi R. BahcallFormer President and Chief Executive Officer$1,610,630
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$541,550
Vojo VukovicSenior Vice President, Chief Medical Officer$942,231
Amar SinghFormer Senior Vice President, Chief Business Officer$385,350
Keizo KoyaSenior Vice President, Drug Development$708,214

Safi R. Bahcall — Former President and Chief Executive Officer — received the highest compensation: $1,610,630 in total.

In addition, Vojo Vukovic — Senior Vice President, Chief Medical Officer — received a total compensation of $942,231; Keizo Koya received $708,214; Keith S. Ehrlich received $541,550; Amar Singh received $385,350.

2010

NamePositionCompensationDetails
Vojo VukovicSenior Vice President, Chief Medical Officer$670,156
Amar SinghSenior Vice President, Chief Business Officer$649,558
Keizo KoyaSenior Vice President, Drug Development$685,443
Safi R. BahcallPresident and Chief Executive Officer$1,226,411
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$496,034

Safi R. Bahcall — President and Chief Executive Officer — received the highest compensation: $1,226,411 in total.

In addition, Keizo Koya — Senior Vice President, Drug Development — received a total compensation of $685,443; Vojo Vukovic received $670,156; Amar Singh received $649,558; Keith S. Ehrlich received $496,034.

2009

NamePositionCompensationDetails
Safi R. BahcallPresident and Chief Executive Officer$869,229
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$382,740
Keizo KoyaSenior Vice President, Drug Development$452,874
Vojo VukovicSenior Vice President, Chief Medical Officer$646,085
Michael P. BaileySenior Vice President, Business Development, Chief Business Officer$500,133
Jeremy G. ChadwickSenior Vice President, Program Management and Clinical Operations$462,881

Safi R. Bahcall — President and Chief Executive Officer — received the highest compensation: $869,229 in total.

In addition, Vojo Vukovic — Senior Vice President, Chief Medical Officer — received a total compensation of $646,085; Michael P. Bailey received $500,133; Jeremy G. Chadwick received $462,881; Keizo Koya received $452,874; Keith S. Ehrlich received $382,740.

2008

NamePositionCompensationDetails
Safi R. BahcallPresident and Chief Executive Officer$1,029,515
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$417,173
Keizo KoyaSenior Vice President, Drug Development$534,517
James G. BarsoumSenior Vice President, Research$688,252
Eric W. JacobsonSenior Vice President, Clinical Research and Regulatory Affairs, Chief Medical Officer$650,273

Safi R. Bahcall — President and Chief Executive Officer — received the highest compensation: $1,029,515 in total.

In addition, James G. Barsoum — Senior Vice President, Research — received a total compensation of $688,252; Eric W. Jacobson received $650,273; Keizo Koya received $534,517; Keith S. Ehrlich received $417,173.

2007

NamePositionCompensationDetails
Safi R. BahcallPresident and Chief Executive Officer$884,797
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$438,580
James G. BarsoumSenior Vice President, Research$720,621
Eric W. JacobsonSenior Vice President, Clinical Research and Regulatory Affairs, Chief Medical Officer$692,660
Keizo KoyaSenior Vice President, Drug Development$775,560

Safi R. Bahcall — President and Chief Executive Officer — received the highest compensation: $884,797 in total.

In addition, Keizo Koya — Senior Vice President, Drug Development — received a total compensation of $775,560; James G. Barsoum received $720,621; Eric W. Jacobson received $692,660; Keith S. Ehrlich received $438,580.

2006

NamePositionCompensationDetails
Safi R. BahcallPresident and Chief Executive Officer$1,087,384
Keith S. EhrlichVice President, Finance and Administration, Chief Financial Officer$515,450
James G. BarsoumSenior Vice President, Research$629,034
Eric W. JacobsonSenior Vice President, Clinical Research and Regulatory Affairs, Chief Medical Officer$570,388
Keizo KoyaSenior Vice President, Drug Development$670,989

Safi R. Bahcall — President and Chief Executive Officer — received the highest compensation: $1,087,384 in total.

In addition, Keizo Koya — Senior Vice President, Drug Development — received a total compensation of $670,989; James G. Barsoum received $629,034; Eric W. Jacobson received $570,388; Keith S. Ehrlich received $515,450.